TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with type 2 diabetes with cardiovascular risk factors (\*) who treated with diet, exercise or antidiabetic medications~* Patients who were treated with statins for 8 weeks or longer~* Patients with low-density lipoprotein cholesterol equal to or greater than 100 mg/dL in the at least one of three measurements after the administration of statins~* Patients with glycerated hemoglobin (HbA1c, NGSP) equal to or greater than 6.0 % (7.0 % if patients were not treated with dipeptidyl-peptidase 4 inhibitors) and lesser than 10.5 %~(\*) cardiovascular risk factors were any of following conditions~1. Presence of stenosis (\>=25%) or plaque on the previous coronary angiography or coronary CT~2. Presence of coronary calcification on the previous coronary CT~3. History of acute coronary syndrome~4. History of percutaneous coronary intervention or coronary artery bypass graft~5. History of stroke (ischemic stroke or hemorrhagic stroke)~6. History of transient ischemic attack~7. History of peripheral artery diseases or aortic disorders~8. Ankle-Brachial Index (AMI) equal to or less than 0.9 in the past measurement~9. Presence of carotid artery plaque (including Max IMT \>=1.1mm) on carotid ultrasonography in the past~Exclusion Criteria:~* Patients with type 1 diabetes~* Patients with triglyceride equal to or greater than 400 mg/dL in the previous fasting measurements~* Patients with pregnancy, possible pregnancy, or on breast-feeding~* Patients with severe infections, perioperative status, or severe trauma~* Patients with renal dysfunction (creatinine \>= 2.4 mg/dl for men, \>= 2.0 mg/dl for women)~* Patients who were received glucagon-like peptide-1receptor agonists~* Patients whom physician in charge considered inappropriate for the study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anagliptin (Type: ACTIVE_COMPARATOR): Anagliptin 100 mg bid for 52 weeks. Can increase to 200 mg bid if needed.
- Sitagliptin (Type: ACTIVE_COMPARATOR): Sitagliptin 50 mg qd for 52 weeks. Can increase to 100 mg qd if needed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Internet Assisted Obesity Treatment Enhanced With Financial Incentives

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* over 18~* BMI between 25 and 50~* Not currently pregnant or pregnant in the previous 6 months and currently breastfeeding or planning on becoming pregnant in 18 months~* Have a computer at home or at work with flashplayer, access to the internet, and a smart phone (to allow use of step counting aps)~* Free of medical problems that might contraindicate participation in a behavioral weight reduction program containing an exercise component~* Not enrolled in another weight reduction program~* Not currently on medication that would affect weight loss~Exclusion Criteria:~* had a heart attack or stroke in the previous six months~* had weight loss surgery~* lost 10 pounds or more in the previous 6 months~* currently taking medications for weight loss~* required by their doctor to follow a special diet (other than low fat)~* planning to move out of the area within 18 months~* schedule conflicts making it difficult to attend online chats~* live more than 60 minutes driving distance from either University of South Carolina or University of Vermont campuses

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Internet only (Type: ACTIVE_COMPARATOR): Participants will be required to attend a weekly Internet chat session with your group members and one of the behavioral weight control therapists. Participants will learn the principles of managing eating and exercise behaviors in weekly, hour-long chat sessions and by completing weekly lessons. Participants are asked to self-monitor foods and exercise through the use of a smartphone ap. Participants will wear a tracking device that monitors steps. All participants will be contacted via e-mail individually, by their group leader who will monitor their progress and offer advice and encouragement. Meetings are weekly for 24 weeks and monthly for 12 months.
- Internet + Incentives (Type: EXPERIMENTAL): Participants are given the same intervention as described for the internet only group, with the exception that they will have the opportunity to earn financial incentives. Financial incentives will be based on participants weight loss, and compliance with certain weight loss behaviors including meeting exercise goals, self-monitoring foods consumed, and daily weighing and reporting.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~* Patients chronically infected with hepatitis C virus (HCV) genotype 1~* HCV RNA viral load ≥10\*5\* IU/mL at screening~* Naïve or nonresponsive to the current standard of care~Key Exclusion Criteria:~* Cirrhosis~* Hepatocellular carcinoma~* Coinfection with hepatitis B virus, HIV-1 or HIV-2

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (BMS-790052, plus Peginterferon alfa-2b, Ribavirin) (Type: EXPERIMENTAL): Treatment Naive
- Arm B (BMS-790052, plus Peginterferon alfa-2b, Ribavirin) (Type: EXPERIMENTAL): Treatment Naive
- Arm C (Placebo, plus Peginterferon alfa-2b, Ribavirin) (Type: PLACEBO_COMPARATOR): Treatment Naive
- Arm D (BMS-790052, plus peginterferon alfa-2b, Ribavirin) (Type: EXPERIMENTAL): Non-Responder
- Arm E (BMS-790052, plus Peginterferon alfa-2b, Ribavirin) (Type: EXPERIMENTAL): Non-Responder

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Sequential Allocation Study to Determine the ED50 of Dexmetedomidine as an Adjuvant to Lidocaine Intravenous Regional Anesthesia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~• Patients 18 to 70 years of age, ASA physical status I-II, undergoing unilateral hand or forearm surgery (that require 30 minutes or more) under IVRA.~Exclusion Criteria:~•Patients with Raynaud's disease, sickle cell anemia, heart block, allergy to any of the anesthetic drugs used, patients on α-adrenergic agonists, ASA III or IV, emergency surgery and pregnant patients., Weight greater than 100Kg.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: LANK-2: Activated and Expanded NK Cell Immunotherapy Together With Salvage Chemotherapy in Children, Adolescents and Young Adults With Relapsed or Refractary Acute Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients between 0 and 23 years of age with diagnosis of acute lymphoblastic leukemia, in second relapse situation, posttransplant relapse or refractary, or~2. Patients between 0 and 23 years of age with diagnosis of acute myeloblastic leukemia, relapsed or refractary. (Patient must meet inclusion criteria 1 or 2)~3. Lansky index \> 60%~4. Mild (\<2) functional organs alteration (hepatic, renal, respiratory) according to National Cancer Institute criteria (NCI CTCAE v4).~5. Left ventricular ejection fraction \> 39%~6. To grant informed consent in accordance with the current legal regulations.~7. Presence of a compatible haploidentical donor (father or mother or brother).~Exclusion Criteria:~1. Patients with history of bad therapeutical compliance~2. Patients not valid after psycho-social evaluation~3. Positive HIV serology

- Gender: ALL
- Minimum Age: None
- Maximum Age: 23 Years
- Healthy Volunteers: f

Study Arms:
- Activated natural killer cells (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Double-blind Comparative Study of SYR-472

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. The participant is an outpatient.~2. The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.~Exclusion Criteria:~1. The participant has any serious cardiac disease, serious cerebrovascular disorder, or any serious pancreatic or hematological disease.（e.g., subjects who require hospitalization or subjects who were hospitalized within 24 weeks prior to the commencement of the observation period)~2. The participant is considered ineligible for the study for any other reason by the investigator or subinvestigator.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- SYR-472 100 mg (Type: EXPERIMENTAL): None
- Alogliptin 25 mg (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The MiniMed™ 780G Glycemic Control and Quality of Life Study for the Treatment of Pediatric and Adult Subjects With Type 1 Diabetes in France.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Subject is ≥7 years of age.~2. Subject has a clinical diagnosis of type 1 diabetes for more than 1 year as determined via medical records or source documentation by an individual qualified to make a medical diagnosis.~3. Subject has a HbA1c value greater than 6.5% and less than 12% at time of enrolment visit.~4. Subject is under Continuous Subcutaneous Insulin Infusion (CSII) therapy (with or without Continuous Glucose Monitoring) ≥ 6 months before enrolment.~5. Subject requires ≥8 units of insulin per day.~6. Subjects and their parent(s)/guardian(s) must be able to speak and be literate in French as verified by the investigator.~7. Subjects and their parent(s)/guardian(s) are willing to participate in the study and sign the Data Release Form (DRF).~8. Subjects who are ≥18 years of age should be able to provide consent.~Exclusion Criteria:~1. Subject has MiniMed™ 780G System IFU contraindication(s).~2. Subject uses Predictive Low-Glucose Management (PLGM) System (i.e. MiniMed™ 640G with SmartGuard) in the last 6 months before the enrolment.~3. Subject uses Low Glucose suspend (LGS) feature (i.e. MiniMed™ Paradigm Veo Pump) in the last 6 months before the enrolment.~4. Subject under Multiple-Daily Injections (MDI) treatment in the 6 months before the enrolment.~5. Subject has any unresolved adverse skin condition in the area of sensor placement (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection).

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- MiniMed™ 780G System (Type: None): Subject will use the MiniMed™ 780G System as per standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* At least 18 years of age at screening~* HbA1c ≥ 8% and ≤ 12% at screening~* Fasting plasma glucose (FPG) ≤ 270 mg/dL (15mmol/L)~* Stable dose metformin ≥ 1500 mg per day with or without a stable dose of sulfonylurea (defined as at least 50% maximal dose per local label) for at least 8 weeks~* estimated glomerular filtration rate (eGFR) \&lt; 60 ml/ml/1.73m2~* Body Mass Index ≤ 45.0 kg/m2~Exclusion Criteria:~* Clinical diagnosis of Type 1 diabetes~* History of ketoacidosis~* Renal, hepatic or pancreatic disease~* Impairment of renal function (defined as creatinine clearance \[CrCl\] \< 60 mL/min~* Cardiovascular or vascular diseases identified within 3 months of participationImpairment of renal function (defined as creatinine clearance \[CrCl\] \< 60 mL/min

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Saxagliptin/Dapagliflozin/Metformin (Type: EXPERIMENTAL): Oral route. Saxagliptin/Dapa adminsitered once daily for 24 weeks at a dose of 5 mg Saxagliptin and 10 mg Dapagliflozin
- Insulin Glargine, Lantos/Metformin (Type: ACTIVE_COMPARATOR): Insulin glargine administered once a day with starting dose of 0.2 Unit per kg or 10 units.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Treatment With Bosentan and Sildenafil to Patients With Eisenmengers Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Eisenmenger syndrome~* Negative pregnancy test~Exclusion Criteria:~* Elevated liver enzymes to more than 3´times normal value~* Hypotension (SBP \< 90 mmhg).~* Mandatory treatment with nitrates~* Myocardial infarction within 3 months~* Stroke within 3 months~* Known allergy to Bosentan or Sildenafil~* inherited degenerative diseases in retina~* Breast feeding~* Suspicion of risc of noncompliance.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Pramipexole for Treatment-Resistant Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets diagnostic criteria for major depressive disorder~* Meets criteria for current major depressive episode~* Score of at least 18 on the Montgomery-Asberg Depression Rating Scale (MADRS) at the baseline visit~* Currently being treated with antidepressant monotherapy at an adequate dose for 6 weeks or willing to enter open lead-in treatment~* Agrees to use an effective form of contraception throughout the study~Exclusion Criteria:~* Pregnant~* At risk for suicide or homicide~* Unstable medical illness (e.g., cardiovascular, liver, kidney, respiratory, endocrine, or neurologic disease, including uncontrolled seizure disorder)~* History of a substance use disorder within 6 months of study enrollment~* History of or current psychotic features~* Currently being treated with typical or atypical antipsychotic medications~* Currently being treated with a medication known to significantly decrease pramipexole clearance (e.g., cimetidine, ranitidine, diltazem, verapamil, quinine or triamterene)~* Clinical or laboratory evidence of untreated hypothyroidism~* History of a 2-week or longer course of pramipexole~* Intolerance of pramipexole at any dose~* Any investigational psychotropic drug use within the last three months~* Level 3 or greater antidepressant resistance as assessed by the ATHF~* Three or more episodes of self-harm in the year prior to study enrollment~* Documented history of poor treatment adherence or frequently missed appointments~* Parkinson's disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Sugar pill (Type: PLACEBO_COMPARATOR): Placebo
- Pramipexole (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Unequivocal histologic diagnosis of ALL~* Detection of the t(9;22)(q34;q11) or 3-way variant by metaphase cytogenetics or BCR-ABL positive by molecular analysis (RT-PCR or fluorescence in situ hybridization \[FISH})~* Prior Therapy:~  * Complete or partial remission following one course of induction chemotherapy with an intensive 4 or 5 drug regimen (with or without imatinib mesylate) on a CALGB or SWOG ALL protocol for previously untreated ALL patients~    * Note: The double induction regimen of SWOG S0333 is considered to be one course of induction chemotherapy for the purpose of this eligibility criterion; therefore, patients from S0333 may be eligible for this study only after completing the entire double induction regimen~ * Complete or partial remission following one course of therapy on any standard induction regimen (with or without imatinib mesylate) without prior enrollment on a cooperative group frontline protocol; in these instances, documentation of Philadelphia chromosome (Ph)+ positivity may occur outside a CALGB or SWOG laboratory~    * Note: CALGB institutions must enroll patients on CALGB 9862 and submission of an initial sample for the companion trial must occur at time of enrollment on CALGB C10001; enrollment on companion studies CALGB 8461 and 9665 is not required~* No more than six weeks of prior imatinib mesylate during induction therapy before study enrollment~* Non-pregnant and non-nursing; treatment under this protocol would expose an unborn child to significant risks; women and men of reproductive potential should agree to use an effective means of birth control and contraception should continue for three months after the last dose of imatinib mesylate (Gleevec) to allow complete clearance of drug and its principle metabolites from the body; in women of childbearing potential, a pregnancy test will be required at study entry

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 59 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (imatinib mesylate, chemotherapy, PBSCT) (Type: EXPERIMENTAL): See Detailed Description.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Double Blind Clinical Trial of DCS for Food Anxiety

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with Anorexia Nervosa, Bulimia Nervosa, Eating Disorder Not Otherwise Specified~Exclusion Criteria:~* Pregnant or planning on becoming pregnant~* Psychotic or Manic

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Setraline (Type: EXPERIMENTAL): 250 mg DCS (setraline) versus placebo plus exposure
- placebo (Type: PLACEBO_COMPARATOR): Placebo group plus exposure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reasoning Training in Individuals With Bipolar Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must have physician or psychiatrist authorization form confirming participant fulfills 4 criteria:~  1. has diagnosis of Bipolar I or II~ 2. has been stable and consistent with medication for last 3 months~ 3. is in a euthymic, rather than manic or depressive, state~ 4. is appropriate for a group-based intervention~     EXCLUSION CRITERIA:~* Not a native English speaker~* Less than 12 years education~* Additional psychiatric diagnosis

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Cognitive training (Type: EXPERIMENTAL): Advanced reasoning training

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete